Director Dealing

BiVictriX Therapeutics PLC

02 September 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park,  2 September 2024 BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces the following dealing in the  Company's ordinary shares of 1 pence each ("Ordinary Shares").

On 30 August 2024, Mr Robert Hawkins, a Non-Executive Director, carried out a 'Bed and ISA' transfer of20,000 Ordinary Shares from his ISA account into a share dealing account (the "Transfer"). The shares were sold for 7.26 pence per Ordinary Shares and immediately repurchased at 7.92 pence per Ordinary Share.

Following the Transfer, Robert Hawkins remains beneficially interested in 325,000 Ordinary Shares which equates to 0.39 per cent. of the Company's total issued share capital.

ENDS

BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman	Email: [e-mail]
SP Angel Corporate Finance LLP (NOMAD and Broker) David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking)	Tel: [phone]
Panmure Liberum Limited (Joint Broker) Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden	Tel: [phone]
ICR Consilium       Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe	Tel: [phone] Email: [e-mail]

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Find out more at www.bivictrix.com and connect with us on LinkedIn and Twitter @BiVictriX.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robert Hawkins
2.	Reason for the Notification
a)	Position/status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	BiVictriX Therapeutics plc
b)	LEI	213800ZI85IZNA6N3L53
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 pence each GB00BNXH3K91
	Identification code
b)	Nature of the transaction	(i)            Sale of 20,000 Ordinary Shares from ISA account (ii)           Purchase of 20,000 Ordinary Shares from share dealing account
c)	Price(s) and volume(s)	Price(s) Volume(s) (i)            7.26 pence (ii)           7.92 pence 20,000 20,000
d)	Aggregated information: -  Aggregated volume -  Price	N/A single transaction
e)	Date of the transaction	30 August 2024
f)	Place of the transaction	AIM, London Stock Exchange

 

END